Departments of Pathology.
Fleury Group Hematology and Flow Cytometry Service, Discipline of Hematology and Hemotherapy, Federal University of São Paulo.
Am J Surg Pathol. 2023 Jan 1;47(1):111-123. doi: 10.1097/PAS.0000000000001991. Epub 2022 Nov 2.
To compare the diagnostic accuracy of core needle biopsies (CNBs) and surgical excisional biopsies (SEBs), samples of lymphoid proliferation from a single institution from 2013 to 2017 (N=476) were divided into groups of CNB (N=218) and SEB (N=258). The diagnostic accuracy of these samples was evaluated as a percentage of conclusive diagnosis, according to the World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues . The contribution of clinical data, the assessment of sample adequacy by a pathologist during the procedure, the number and size of fragments, the needle gauge, the ancillary tests, and the type of lymphoid proliferation were also examined. The diagnostic accuracy of SEB was 97.3% and CNB 91.3% ( P =0.010). Additional factors considered essential for establishing the final diagnosis in some cases were: clinical information (20.6% CNB, 7.4% SEB; P <0.001); immunohistochemistry (96.3% CNB, 91.5% SEB; P =0.024); flow cytometry (12% CNB, 6.8% SEB; P =0.165); and other complementary tests (8.2% CNB, 17.3% SEB; P =0.058). Factors that did not influence performance were the evaluation of sample adequacy during the procedure, the number and size of fragments, and the needle gauge. Increased percentage of nondiagnostic CNB was observed in T-cell lymphomas (30%), followed by classic Hodgkin lymphoma (10.6%). The main limitation of CNB was the evaluation of morphologically heterogenous diseases. CNB is useful and safe in lymphoma diagnosis provided it is carried out by a team of experienced professionals. Having an interventional radiology team engaged with pathology is an essential component to achieve adequate rates of specific diagnoses in CNB specimens.
为了比较核心针活检(CNB)和外科切除活检(SEB)的诊断准确性,我们将 2013 年至 2017 年来自单一机构的淋巴增生样本(N=476)分为 CNB 组(N=218)和 SEB 组(N=258)。根据世界卫生组织(WHO)造血和淋巴组织肿瘤分类,我们评估这些样本的诊断准确性为明确诊断的百分比。还检查了临床数据、病理医生在操作过程中对样本充足性的评估、样本碎片的数量和大小、针规、辅助检查以及淋巴增生类型的作用。SEB 的诊断准确率为 97.3%,CNB 为 91.3%(P=0.010)。在某些情况下,认为对最终诊断至关重要的其他因素包括:临床信息(20.6% CNB,7.4% SEB;P<0.001);免疫组织化学(96.3% CNB,91.5% SEB;P=0.024);流式细胞术(12% CNB,6.8% SEB;P=0.165)和其他补充检查(8.2% CNB,17.3% SEB;P=0.058)。不影响性能的因素是在操作过程中对样本充足性的评估、样本碎片的数量和大小以及针规。T 细胞淋巴瘤(30%)的非诊断性 CNB 比例增加,其次是经典霍奇金淋巴瘤(10.6%)。CNB 的主要局限性是评估形态学异质性疾病。如果由经验丰富的专业团队进行,CNB 对淋巴瘤诊断是有用且安全的。有介入放射科团队与病理科合作是实现 CNB 标本特定诊断率的重要组成部分。